Lyn-analyse: Nye tal udløser spænding forud for Novo-regnskab

Der er én kæmpe joker i spil, når Novo Nordisk med Mike Doustdar præsenterer halvårsregnskab om to uger. Selskabet nye fedmepille kommer til at fylde det hele, og helt nye recepttal gør ikke spændingen mindre. Analytikerne håber på en opjustering - alt andet vil være en skuffelse.  Hør i denne Lyn-analyse, hvad de nye recepttal indikerer og hvor konkurrenten Eli Lilly er med deres modtræk, Fundayo-pillen.  Gæst: Lone Andersen, journalist, Finans.  Vært: Mads Ring.  Foto: Novo Nordisk.See omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Jul 22, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Lyn-analyse: Nye tal udløser spænding forud for Novo-regnskab

0:00 8:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Finans Podcast?

This episode is 8 minutes long.

When was this Finans Podcast episode published?

This episode was published on July 22, 2026.

Can I download this Finans Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!